AIM IMMUNOTECH INC. Equity Securities, FV-NI, Gain (Loss)
AIM IMMUNOTECH INC. (AIM) reported Equity Securities, FV-NI, Gain (Loss) of -$177.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2024-08-14
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for the quarter ending 2024-06-30 was -$85.00K.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for the quarter ending 2024-03-31 was -$92.00K, a 131.72% decline year-over-year.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for the quarter ending 2023-12-31 was $401.00K, a 350.56% increase year-over-year.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for the quarter ending 2023-09-30 was -$309.00K.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was $200.00K.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$1.68M.
- AIM IMMUNOTECH INC. equity securities, fv-ni, gain (loss) for fiscal 2021 was -$88.00K.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | -$85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$177.00K 10-Q · filed 2024-08-14 | $224.00K derived: sum of 3 quarters · filed 2024-08-14 | -$85.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2024-03-31 | -$92.00K 10-Q · filed 2024-05-15 | $309.00K derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-05-15 | -$181.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $92.00K derived: sum of 2 quarters · filed 2024-04-01 | -$89.00K derived: sum of 3 quarters · filed 2024-08-14 | $200.00K 10-K · filed 2024-04-01 | |
| 2023-09-30 | -$309.00K 10-Q · filed 2023-11-14 | -$490.00K derived: sum of 2 quarters · filed 2024-08-14 | -$201.00K 10-Q · filed 2023-11-14 | -$111.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-06-30 | -$181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $109.00K 10-Q · filed 2024-08-14 | $198.00K derived: sum of 3 quarters · filed 2024-08-14 | -$167.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $290.00K 10-Q · filed 2024-05-15 | $379.00K derived: sum of 2 quarters · filed 2024-05-15 | $14.00K derived: sum of 3 quarters · filed 2024-05-15 | -$456.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$276.00K derived: sum of 2 quarters · filed 2024-04-01 | -$746.00K derived: sum of 3 quarters · filed 2024-04-01 | -$1.68M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$365.00K 10-Q · filed 2023-11-14 | -$835.00K derived: sum of 2 quarters · filed 2023-11-14 | -$1.77M 10-Q · filed 2023-11-14 | -$1.77M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.40M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | -$934.00K 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | -$88.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |